By Michael Dabaie

Roche Holding AG's (RHHBY) Genentech said the U.S. Food and Drug Administration approved Rituxan, in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in pediatric patients 2 years of age and older.

GPA and MPA are rare, potentially life-threatening diseases affecting small- and medium-sized blood vessels.

This approval is the first pediatric indication for Rituxan, Genentech said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

September 27, 2019 14:17 ET (18:17 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Roche (QX) Charts.